BiotechTube
Home/Pipeline/Bispecific (Undisclosed)

Bispecific (Undisclosed)

Undisclosed

PreclinicalActive

Key Facts

Indication
Undisclosed
Phase
Preclinical
Status
Active
Company
MacroGenics

About MacroGenics

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop life-changing medicines for patients with cancer. The company has built a broad pipeline of investigational product candidates, including its lead bispecific DART® molecule lorigerlimab, and has established strategic collaborations with global pharmaceutical companies. With in-house GMP manufacturing capabilities and a focus on innovative antibody engineering, MacroGenics aims to address significant unmet needs in oncology.

View full company profile

Therapeutic Areas

OncologyAutoimmune (via partnered TZIELD)

Other Undisclosed Drugs

DrugCompanyPhase
ASPEN Study ProgramInsmedPhase 3
ARISE Study ProgramInsmedPhase 3
MGL-2086Madrigal PharmaceuticalsPhase 1
Innovative Proprietary/Licensed ProductsLaboratorios Farmaceuticos RoviVarious
Undisclosed Partnered ProgramSepternaDiscovery
Undisclosed Cell TherapyImmix BiopharmaPre-clinical
HTL0039732Nxera PharmaPreclinical
LYT-310PureTech HealthPreclinical
Sec61 Portfolio AssetsKezar Life SciencesPreclinical
WTX-518Werewolf TherapeuticsPreclinical
WTX-712Werewolf TherapeuticsPreclinical
Measovir®-based Prophylactic Vaccine (with Unither)OncovitaResearch/Pre-clinical